Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients
- 1 January 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 30 (1) , 24-28
Abstract
Congenital factor VII (FVII) deficiency is a rare bleeding disorder with an estimated prevalence of 1 per 500 000 in the general population. On-demand replacement therapy is the main therapeutic choice in patients with congenital FVII deficiency. Inhibitor formation against exogenous FVII is very rare and can cause challenges in the management of the disorder. The present study was conducted to assess the prevalence of FVII inhibitor in 50 patients with congenital FVII deficiency under on-demand or prophylaxis treatment by recombinant activated FVII. All patients with confirmed congenital FVII deficiency were assessed for inhibitor development in regular intervals. Inhibitor titer was determined by a modified Nijmegen–Bethesda assay. The study results were analyzed by SPSS software. Among all cases, two patients (4%) developed an FVII inhibitor. Case 1 was a 14-year-old boy with severe FVII deficiency (FVII activity <1%) with regular prophylaxis. The patient was a high-responder with high-titer FVII inhibitor (170 Bethesda Unit). This patient, who had a history of intracranial hemorrhage, had undergone brain surgery three times. The second patient was a 70-years old man with on-demand therapy that also developed a high-titer inhibitor (10 Bethesda Unit). This patient had experienced easy bruising and endured a few surgeries for his brain tumor and, finally, succumbed to the disease. Although the inhibitor formation is a rare phenomenon, it may result in a significant challenge to manage the affected patients.Keywords
This publication has 14 references indexed in Scilit:
- Inhibitor development after liver transplantation in congenital factor VII deficiencyHaemophilia, 2016
- Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technologyThrombosis Research, 2016
- A new report of FVII‐inhibitor in a patient suffering from severe congenital FVII deficiencyHaemophilia, 2015
- Nijmegen-Bethesda Assay to Measure Factor VIII Inhibitors2013
- Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severityJournal of Thrombosis and Haemostasis, 2012
- Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding DisordersJournal of Thrombosis and Haemostasis, 2012
- Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVIIHaemophilia, 2011
- Factor VII DeficiencySeminars in Thrombosis and Hemostasis, 2009
- Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G)European Journal of Haematology, 2007
- Acquired factor VII deficiency in hematopoietic stem cell transplant recipientsBone Marrow Transplantation, 2002